Shareholders in ProQR Therapeutics (NASDAQ:PRQR) Are in the Red If They Invested Five Years Ago
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
ProQR Therapeutics Price Target Maintained With a $2.50/Share by Chardan Capital
HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics with a Buy and maintains $5 price target.
ProQR Therapeutics Reports Quarterly Financials
ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate
ProQR Therapeutics Q1 2024 GAAP EPS €(0.09) Misses €(0.07) Estimate, Sales €4.450M Beat €3.144M Estimate
ProQR Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
ProQR Therapeutics Had EUR102.7 M as of End of 1Q Providing Runway Into Mid-2026 >PRQR
ProQR Therapeutics Had EUR102.7 M as of End of 1Q Providing Runway Into Mid-2026 >PRQR
ProQR Therapeutics 1Q Loss/Shr EUR0.09 >PRQR
ProQR Therapeutics 1Q Loss/Shr EUR0.09 >PRQR
ProQR Therapeutics' RNA Program Shows Promise
ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer RNA Editing
ProQR Therapeutics Announces Board Nomination and AGM
ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics NV (Nasdaq: PRQR) today announced it will present new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx
ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.The opposition was filed in June 2021 with the
ProQR Therapeutics Is Maintained at Neutral by Citigroup
ProQR Therapeutics Is Maintained at Neutral by Citigroup
ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup
ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup
ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics with a Buy and raises the price target from $2 to $2.5.
No Data